The “Diabetic Platelet”

    


    


    Figure 1: Impact of hyperglycaemia on platelet function.

    

Non-enzymatic glycation of platelet membrane proteins that decreases membrane fluidity, which may increase platelet adhesion [28],

Osmotic effect of glucose that activates platelet GP IIb/IIIa and P-selectin expression [29],

Activation of protein kinase C, a mediator of platelet activation [30], and

Glycation of circulating Low-Density Lipoproteins (LDL), which increases intracellular calcium concentration and Nitric Oxide (NO) production [31].

It has been shown that challenging healthy non-diabetic subjects’ with24h hyperglycaemia-hyperinsulinemia altered the insulin signalling pathway [32]. Indeed, there is an upregulation on mRNA and protein levels of both glycogen synthase kinase 3Β (GSKΒ3) and tyrosine phosphatase SHP2 as well as tissue factor, while in the meantime there is a downregulation on mRNA for the syntaxin 4-binding protein. High glucose can also increase Calcium influx in platelets is also increased during high glucose levels through enhancement of the PI3K-dependent transient receptor potential channel canonical type 6 [33]. The latter is well-known to be significantly extremely expressed in diabetic platelets. Hyperglycaemia is able to increase the expression and/or activity of Protein Kinase C (PKC) [30], a central kinase in the regulation of platelet activity. hyperglycaemia affects simultaneously the mitochondrial function in platelets. One of the recent components that link hyperglycaemia and mitochondrial dysfunction is the activation of aldose reductase and subsequent ROS production which result to p53 phosphorylation [34] or the stimulation of the PLC?2/PKC/p38aMAPK pathway and the increase in TXA2 production [35]. More recent studies reported that the platelet activation due to hyperglycaemia could be involved into the down regulation of different micro-RNA (miR) such as miR- 223 and miR-146a. It was found that low platelet and plasmamiR-223 and miR-146a expression has been related with an increased risk for ischemic stroke in patients with diabetes mellitus [36]. Many of the harmful effects of glucose have been associated to its metabolite Methylgyloxal (MG). It is known that plasma levels of MG in diabetic patients are higher. Study examining the effect of MGon platelets showed that it increases intracellular Ca2+ levels and activates classical PKCs while inhibiting PI3K/Akt and the Β3-integrinoutsidein signalling. Moreover, in vivo, MG increases thrombus size but reduces its stability in mice [37]. Although most of the effects of MG have been attributed to the formation of Advanced Glycation Endproducts (AGEs) and the subsequent activation of the AGE receptor, studies showed a direct effect of MG on platelets which may contribute to the diabetes-associated platelet hyperaggregability. The expression of surface markers such as P-select in (CD62) and CD63 (a lysosomal glycoprotein) has been shown to be significantly augmented by AGE stimulation [38] suggesting AGE-induced platelet degranulation. Studies done in mice could show that AGEs develop a prothrombotic phenotype via interaction with platelet glycoprotein IV (CD36) [39]. The serum- and glucocorticoid-inducible kinase 1 (SGK1) has been equally suggested mediating AGE-induced platelet hyper activation [40]. In platelets, SGK1 intensify Store-Operated Calcium Entry (SOCE) and so controls several Ca2+-dependent platelet functions such as degranulation, phosphatidylserine exposure, integrin aIIbΒ3 activation, aggregation and thrombus formation. Here, it is worth mentioning that hyperglycaemia also stimulates thrombotic events through plasmatic mechanisms. In particular, hyperglycaemia activates coagulation by raising concentrations of procoagulant factors (e.g. tissue factor, von Willebrand factor) [41] and inhibits fibrinolysis by increasing concentrations of plasminogen activator inhibitor.

Insulin Deficiency and Resistance

The vast majority of DM patients can be grouped to two broad aetiopathogenetic categories. Type-1 DM, which accounts for only 5–10% of cases, results from a cellular-mediated autoimmune destruction of Β-cells of the pancreas, leading to an absolute deficiency of insulin secretion. Type-2 DM, which accounts for around 90–95% of DM individuals, is caused by a combination of resistance to insulin action and an inadequate compensatory insulin secretory response, usually having relative insulin deficiency [16].

Deficient insulin action is the fundamental factor for development of DM and clearly contributes to platelet dysfunction [42]. Both Insulin Receptors (IR) and Insulin-like Growth Factor-1 (IGF-1) receptors are expressed in platelets [43]. Among other effects in platelets, insulin increases surface expression of adenylate cyclaselinked prostacyclin (PGI2) receptor and induces the release of plasminogen activator. IGF-1 is existing in alpha granules of platelets and high levels of its functional receptor are expressed on the platelet surface, which may be involved to the amplification of platelet responses. IGF-1 stimulation of platelets results in dose-dependent phosphorylation of the IGF receptor and in tyrosine phosphorylation of Insulin Receptor Substrate-1 (IRS-1) and IRS-2, stimulating their subsequent binding with the p85 subunit of Phosphoinositide-3 kinase (PI3K), leading to phosphorylation of protein kinase B, which is involved in several cellular responses to insulin and IGF-1, including modulation of platelet reactivity [44].

Several anomalies in insulin-mediated signalling pathways, which can be categorized as IRS-dependent and independent factors, have been proposed to contribute to the vulnerable or ended plateletinhibitory effect detected in patients with insulin resistance [42,45]. Among IRS-dependent factors, insulin resistance causes increased intracellular calcium concentration that leads to augmented platelet degranulation and aggregation [46]. Among IRS-independent pathways contribute to platelet dysfunction due to insulin resistance, the role of reduced platelet sensitivity to NO and PGI2 is remarkable, since both molecules released by the endothelium delay platelet activation; consequently, an impaired response is related with superior platelet reactivity [47]. Further, a recent study found connection between improvement of insulin sensitivity, measured by the Homeostasis Model Assessment (HOMA) of insulin resistance, and changes of platelet function [48].

The significance of insulin resistance in platelet hyperreactivity among patients with DM is underlined by recent studies with thiazolidinediones in which this group of insulin sensitizers has shown a positive effect on platelet function. For instance, rosiglitazone therapy has been associated in some preliminary studies with better sensitivity to NO and partial control of intracellularcalcium concentrations in DM patients [49]. There are controversial data regarding the proposed benefit of insulin-sensitizer therapy over insulin-providing therapy in terms of atherosclerosis progression and cardiovascular outcomes. The PERISCOPE [50] showed that Pioglitazone, an insulin-sensitizer, therapy was related with a significantly lower rate of atherosclerosis progression at 18 months, when compared with glimepiride, an insulin secretagogue, treatment. The result also has been reported in SYMPHONY substudy [51]. Although these studies highlighted the central role of insulin resistance in progression of atherothrombotic events in DM patients, these outcomes have not been established in the later published APPROACH trial [52]. In this study, there was no significant difference between the group treated with thiazolinedione rosiglitazone and the group treated with glipizide, an insulin secretagogue, in patients with type-2 DM and CAD [52].

Related Metabolic Conditions

Several metabolic conditions connected with type-2 DM may are responsible for the increased platelet reactivity saw in these patients, including obesity, dyslipidaemia and increased systemic inflammation.

Obesity is a common characteristic in patients with type-2 DM. First of all obesity itself may be associated with insulin resistance, which has relevant effects on platelet reactivity as described above. Nevertheless, other factors present in obese patients may be the reason for platelet dysfunction, which include:

Overall, these metabolic abnormalities observed to obese patients eventually lead to increased platelet reactivity [53,54]. Russo et al. recently reported that weight loss returned the sensitivity to NO and PGI2 and reduced platelet activation [48]. In any case, response to anti platelet drugs, mainly to clopidogrel, is impaired in persons with high body mass index [55].

Dyslipidaemia is also common among the type-2 DM patients. It is typically expressed by elevated triglycerides and low High- Density Lipoprotein (HDL) cholesterol. Hypertriglyceridemia is a characteristic manifestation that is known to enhance platelet activation [56]. Triglyceride-rich Very-Low-Density Lipoprotein (VLDL) particles also influences the coagulation cascade and harmsthe fibrinolysis, thus predisposing to atherothrombosis [57]. The recommended mechanism to elucidate the effects of triglycerides on platelet function is the apoE content of VLDL particles and their contact with the platelet LDL receptor [58]. Moreover, the thrombotic properties of LDL seem to be rather related to its oxidation. The oxidized-LDL can directly interact with platelets specific receptors such as the lectin-likeoxidized LDL receptor-1 [59] or the CD36 [60,61] and contribute to platelet’s activation. Not only ox-LDL activates platelets but activated platelets are also known to be able to produce ox-LDL upholding the vicious cycle. Low levels of HDL are related with endothelial dysfunction, which increases the atherothrombotic risk in DM patients. On the other hand, intravenous administration of reconstituted HDL rapidly controls the endothelial function by increasing NO bioavailability in patients with hypercholesterolaemia [62]. Similarly, Calkin et al reported that reconstituted HDL caused a reduction of platelet aggregability in DM patients by flowing out cholesterol from platelets [63].

DM is a medical condition characterized by systemic inflammation. Indeed, DM patients have higher concentrations of inflammatory, platelet activation and coagulation markers, such as soluble CD40 lig and, soluble P-select in, interleukin-6, and tissue factor, compared with healthy subjects [64]. Furthermore, inflammation modifies the expression of Fc gamma RIIA receptor, which is higher in platelets of DM patients and helps to platelet activation [65].

Additional Cellular Abnormalities

Several studies have proved that other platelet anomalies common in DM patients may cause their hyperreactivity status, including dysregulation of calcium metabolism, oxidative stress, upregulation of P2Y12 signalling pathway and accelerated platelet turnover.

Platelets from patients with DM have increased intracellular calcium levels due to impaired modulation of calcium metabolism. The factors involved in calcium signalling abnormalities in DM patients are not fully clarified. Mechanisms that have been proposed to impair calcium homeostasis and, consequently, in platelet hyperreactivity are: a) disproportionate influx of calcium through the sodium/calcium exchanger [66], b) alterations in the activity of calcium ATPases [67], c) reduced sensitivity to insulin, which decreases sarcoplasmic endoplasmic reticulum calcium-ATPase (SERCA-2) [42,49], and d) increased oxidative stress, which induces calcium signalling due to increased formation of superoxide anions and reduced nitric oxide production [68]. The final result of this altered calcium homeostasis is an augmented concentration of cytosolic calcium, which leads to enhanced platelet reactivity and aggregation [42].

Platelet function is influenced by the presence of reactive oxygen species as well as by the regulation of platelet or vascular redox status, and the platelets may become prothrombotic [69]. DM is related with oxidative stress, mainly with an overproduction of reactive oxygen and nitrogen species, as well as reduced platelet antioxidant levels [70]. The platelet activation is increased due to excessive generation of potent oxidants, such as superoxide anions and hydrogen peroxide [69,71] An increase in reactive oxygen species along with chronic hyperglycaemia augments production of advanced glycation end products (AGEs) [72]. AGEs may developatherosclerotic complications by activation of the receptor for AGEs (RAGE) [73] and by enhancing platelet aggregation through the serotonin receptor [74]. Further, endothelial function is impaired also by oxidative stress through a reduction in production of NO and PGI2 [75]. This is of particular interest in patients with DM since their platelets have diminished sensitivity to the actions of these vasodilator molecules produced by the endothelium [47]. Recently it has been showed that high blood glucose levels trigger neutrophil release of S100 calciumbinding protein A8/A9 (S100A8/A9), which binds to the receptor for advanced glycation end products (RAGE) on Kupffer cells, ultimately leading to increased Thrombopoietin (TPO) production in the liver. TPO causes megakaryocyte proliferation and consequently thrombocytosis [76].

The platelet Adenosine Diphosphate (ADP) P2Y12 receptor signalling pathway has been suggested to be upregulated in diabetic platelets, in particular those with type-2 DM [77]. This suppresses cAMP concentration and, in addition to a lower responsiveness to insulin, leads to increased adhesion, aggregation, and procoagulant activity [78]. Another abnormality in platelet surface molecules is the increased expression of surface proteins such as P-selectin and glycoproteins Ib and IIb/IIIa, which are integrins that mediate adhesion [53].

An accelerated platelet turnover represented by the presence of a higher number of reticulated platelets has been observed in patients with DM. Reticulated platelets are larger and more sensitive, resulting in platelet hyperreactivity and lower response to antiplatelet therapies including aspirin and clopidogrel [79,80]. In addition, platelets of DM patients are larger, and thus hyperreactive, as platelet size correlates with greater platelet reactivity measured by aggregation and total release of granular content.

Increased Apoptosis

Although being anucleated, there is evidence indicating that platelets have the required machinery to undergo apoptosis [81]. Among other, calpain seems to play an important role in platelet apoptosis [82]. Indeed, caspase activation during platelet apoptosis seems to be downstream of calpain activation. The increased calpain activation observed in DM platelets suggests that diabeticplatelets may be more susceptible to apoptosis. Several factors have been reported to induce platelet apoptosis including the diabetes-associated oxidative stress which is an important stimulus for inducing mitochondrial damage [83]. Mitochondria not only are targeted by the oxidative stress but may also amplify the reaction to oxidative stress due to ROS generation [83,84]. The mitochondrial function of diabetic platelets is altered due to increased ATP content and decreased mitochondrial membrane potential [85]. Another mechanism involved in platelet apoptosis is the development of Endoplasmic Reticulum (ER) stress due to overproduction of AGEs [86] and homocysteine [87].

One of the consequences of platelet activation and apoptosis is the generation of intact membrane vesicles known as microparticles. The formation of platelet-derived microparticles (PMPs) is known to be calcium and calpain dependent. Although PMPs are involved in haemostasis due to their procoagulant properties, elevated levels of PMPs in blood from diabetic patients has been suggested to take part in the increased vascular complications in diabetes [88,89].

Increased Mean Platelet Volume

As mentioned above platelet reactivity and size have been shown to directly correlate. Indeed, young and large platelets exhibit higher activity than old and small ones. The Mean Platelet Volume (MPV) is an indicator of the average size of platelets which has been largely used to investigate the relationship between platelet size and activity. There is evidence that MPV is significantly increased in diabetic patients and that it directly associates with glycaemic control and obesity [90].

Hyporesponsiveness to Anti-Platelet Therapy

One other feature of diabetic platelets is their hyporesponsiveness to anti-platelet therapy. Indeed, there is evidence that anti-platelet therapy is significantly less effective in diabetic patients when compared with patients without diabetes [13]. Diabetic patients are refractory to the anti-platelet effect of aspirin, a phenomenon called “aspirin resistance” [91]. Aspirin or salicylic acid acetylates and irreversibly inhibits cyclooxygenase thus inhibiting the TXA2 formation. Although aspirin resistance is seen in the majority of diabetic patients, the exact molecular mechanism is still blurred. One of the mechanisms suggested to contribute to aspirin-resistance is the increased glycation of platelet proteins which may alter the acetylation process [92]. Many in vitro studies have also shown a direct connection between hyperglycaemia and aspirin resistance. Indeed, high glucose can directly reduce the anti aggregating effect of aspirin by inhibiting the aspirin-induced activation of the NO/ cGMP/PKG pathway without affecting the aspirin induced inhibition of TXA2 synthesis [93]. It also has been suggested that lactic acid might be the mediator of the glucose-induced inhibition of the aspirin effect in platelets [94]. More recently, non-HDL cholesterol has also been reported to be an independent risk factor for aspirin resistance in patients with type 2 diabetes [95].

Diabetes is also known to be associated to a reduced responsiveness of platelets to the P2Y12ADP receptor antagonist clopidogrel [10,96]. Although not directly investigated in diabetic patients, upstream of ADP receptor levels may contribute to clopidogrel resistance.

Conclusions

The fact that the diabetic environment can modulate platelet function in several ways describes the failure of glycaemic control alone to reduce the risk of atherothrombotic events in diabetic patients. Certainly, the increased platelet hyper reactivity is the outcome of complicated inter-regulated mechanisms (Figure 2). Additionally, bearing in mind that diabetic platelets are resistant to most anti-platelet therapy, there is a need of new therapeutical strategies to improve platelet function in diabetes. Definitely, controlling both glycemia and dyslipidaemia may improve the effects of antiplatelet therapy. The understanding of the molecular mechanisms leading to increased platelet reactivity in patients with DM may set the basis for targeted antiplatelet treatment strategies in this high-risk cohort. Thus, the facts that calpain plays an important role in platelet activation and that calpain activity is elevated in diabetic platelets, makes it attractive to propose the Ca2+-activated proteases as a promising therapeutic target to prevent thrombotic complications in diabetic patients.

    


    


    Figure 2: Pathways involved in platelet hyper reactivity in DM patients and therapeutic targets.